Table 2 Outcomes of cohort studies
| Â | All cohort studies | Only definite nephritis | Any SLE patients | ||||||
|---|---|---|---|---|---|---|---|---|---|
Outcome | Number of cohorts | Number of events/patients | Percentage with outcome | Number of cohorts | Number of events/patients | Percentage with outcome | Number of cohorts | Number of events/patients | Percentage with outcome |
Efficacy | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Complete or partial response | 7 | 121/151 | 80 | 7 | 121/151 | 80 | No data | ||
Failure/No response | 8 | 37/176 | 21 | 7 | 30/151 | 20 | 1 | 7/25 | 28 |
Adverse events | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Adverse event discontinuations | 9 | 40/285 | 14 | 4 | 6/68 | 8.8 | 5 | 34/217 | 16 |
Lack of efficacy discontinuations | 5 | 24/235 | 10 | 1 | 4/24 | 17 | 4 | 20/211 | 9.5 |
All infections | 10 | 76/327 | 23 | 4 | 18/70 | 26 | 6 | 58/257 | 23 |
Serious infections | 8 | 8/185 | 4.3 | 4 | 4/87 | 4.6 | 4 | 4/98 | 4.1 |
Gastrointestinal (diarrhoea, nausea, vomiting) | 14 | 122/406 | 30 | 8 | 52/160 | 33 | 6 | 58/257 | 29 |
Leucopaenia | 8 | 6/188 | 3.2 | 4 | 1/61 | 1.6 | 4 | 5/127 | 3.9 |
Vertigo, dizziness | 3 | 6/81 | 7.4 | No data | 3 | 6/81 | 7.4 | ||
Hair loss | 2 | 5/42 | 12 | 1 | 1/13 | 7.7 | 1 | 4/29 | 14 |